Walleye Capital
TGTX icon

Walleye Capital’s TG Therapeutics TGTX Stock Holding History

Walleye Capital’s Portfolio TGTX Stock Details TGTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$475K Buy
14,300
+11,100
+347% +$331K ﹤0.01% 2713
2025
Q4 		$95.4K Sell
3,200
-24,800
-89% -$810K ﹤0.01% 3891
2025
Q3 		$1.01M Sell
28,000
-65,000
-70% -$2.14M ﹤0.01% 2085
2025
Q2 		$3.35M Buy
93,000
+15,800
+20% +$588K 0.01% 1132
2025
Q1 		$3.04M Buy
77,200
+53,300
+223% +$1.79M 0.01% 1125
2024
Q4 		$719K Sell
23,900
-6,200
-21% -$178K ﹤0.01% 2676
2024
Q3 		$704K Sell
30,100
-41,900
-58% -$915K ﹤0.01% 2982
2024
Q2 		$1.28M Buy
72,000
+43,300
+151% +$691K ﹤0.01% 2576
2024
Q1 		$437K Buy
28,700
+19,500
+212% +$311K ﹤0.01% 3316
2023
Q4 		$157K Sell
9,200
-32,900
-78% -$382K ﹤0.01% 3814
2023
Q3 		$352K Buy
42,100
+32,800
+353% +$457K ﹤0.01% 3098
2023
Q2 		$231K Sell
9,300
-3,900
-30% -$101K ﹤0.01% 2992
2023
Q1 		$199K Buy
+13,200
New +$201K ﹤0.01% 2479

Other funds holding TGTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
CAM
Congress Asset Management Boston, Massachusetts $16.3B AUM 42.69% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Walleye Capital's TGTX Position: Q1 2026 in Review

Walleye Capital reduced its TG Therapeutics (TGTX) stake by 97% in Q1 2026, selling an estimated $1.74M and leaving 2,018 shares worth $67K. The position accounts for ﹤0.01% of the portfolio, ranked #3813.

Walleye Capital first reported a position in TGTX in Q4 2019 and has held it in 13 quarters since. The position peaked at $1.81M in Q4 2025. 363 funds tracked by Wall St. Rank hold TGTX as of Q1 2026.

  • Walleye Capital held 2,018 shares of TG Therapeutics worth $67K as of Q1 2026.
  • Walleye Capital sold 58,548 TG Therapeutics shares in Q1 2026, an estimated $1.74M.
  • TG Therapeutics made up ﹤0.01% of Walleye Capital's portfolio in Q1 2026, its #3813 holding.
  • Walleye Capital first reported a position in TG Therapeutics in Q4 2019 and has held it in 13 quarters since.
  • Walleye Capital's TG Therapeutics position peaked at $1.81M in Q4 2025.
  • 363 funds tracked by Wall St. Rank held TG Therapeutics as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.